The research and development of new vaccines is an expensive and risky process. They require heavy investment of time and resources, with no guarante… - Yasmine Belkaid

The private sector may also be reluctant to invest in research into diseases that mainly affect poor countries, as the return on investment is perceived as low due to these countries’ low purchasing power. In addition, the financial risks are high.

we work to strengthen vaccine capacities, by developing new formulations and optimizing production methods to make vaccines more accessible and affordable.

it is important to understand the many obstacles that research institutes face in financing their vaccine research, particularly in developing countries.